

SWIXX BIOPHARMA AG

CHE – 147.465.430

Juridiskās personas kods / Legal entity's code

Neuhofstrasse 5A, 6340, Baar, Switzerland

adrese / address

Register of Commerce of the Canton of Zug

(reģistrs, kurā tiek saglabāti un glabāti uzņēmuma dati / register, where are saved and stored data of the company)

Adresēts tiem, uz kuriem tas var attiekties / Addressed to whom it may concern

**APSTIPRINĀJUMS ATTIECĪBĀ UZ
"THYROGEN" PIEGĀDI**

21.08.2024, PRĀGA

Ņemot vērā, ka Swixx Biopharma AG ir noslēgts līgums ar zāļu "Thyrogen" (Turpmāk – "Zāles"), reģistrācijas apliecības īpašniekiem, kas dod tiesības Swixx Biopharma AG iegādāties un pārdot Zāles, kā arī ir līgums ar Recipe Plus AS, reģistrācijas numurs 40003234547, ar atrašanās vietu Mūkusalas Iela 41b Rīga LV-1004 Latvija, kurai ir tiesības iegādāties Zāles no Swixx Biopharma AG,

ar šo apliecina, ka

Gadījumā, ja Recipe Plus AS tiks atzīts par Nacionālā veselības dienesta atklātā konkursa "Parenterāli ievadāmo zāļu onkoloģisko saslimšanu ārstēšanai iegāde 2025. un 2026.gadam" iepirkuma identifikācijas nr. VM NVD 2024/15 uzvarētāju (Turpmāk – "Tenderis"), Swixx Biopharma AG varēs pārdot Recipe Plus AS nepieciešamos Zāļu daudzumus, kas norādīti Tendera konkursa dokumentācijā.

**CONFIRMATION
REGARDING "THYROGEN" SUPPLY**

21.08.2024, PRAGUE

Taking into account that Swixx Biopharma AG has agreement concluded with the marketing authorization holder for the medicinal product "Thyrogen" (hereinafter referred to as the "Medicinal Product"), which entitles Swixx Biopharma AG to purchase and sale the Medicinal Product, as well having an agreement with Recipe Plus AS, registration number 40003234547, with a seat at Mūkusalas Iela 41b Rīga LV-1004 Latvia, which has a right to purchase the Medicinal Product from Swixx Biopharma AG,

hereby confirm that

in case Recipe Plus AS will be awarded as a winner of public procurement No. VM NVD 2024/15 announced by the National Health Service as the "Purchase of parenterally administered drugs for the treatment of oncological diseases for the 2025 and 2026 years" (hereinafter referred to as the "Public Tender"), Swixx Biopharma AG will be able to sell and Recipe Plus AS will be able to purchase required quantities of the Medicinal Product as indicated in the documentation of the Public Tender.

Izpilddirektors / Chief Executive Officer
Jean - Michel Lespinasse

(paraksts/signature)

Galvenā juriste un uzņēmuma sekretāre /
General Counsel and Company Secretary
Gabriela Zelenkova

(paraksts/signature)

